How Mazur was paid
$4.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Total |
|---|---|---|---|---|---|
| Leonard MazurChief Executive Officer and Executive Chairman | $475,000 | $2,975,000 | $820,440 | $237,500 | $4,507,940 |
| Myron HolubiakExecutive Vice Chairman | $450,000 | $1,487,500 | $343,640 | $225,000 | $2,506,140 |
| Dr. Myron CzuczmanChief Medical Officer | $450,000 | $1,443,750 | $410,220 | $157,500 | $2,461,470 |
What changed and why
- $3.5MCEO total compensation increased from $3,521,268 in 2024 to $4,507,940 in fiscal 2025.
- Stock and option awards for fiscal year 2025 included grants from majority-owned subsidiary Citius Oncology, Inc.
- $238KNon-equity incentive plan compensation for the CEO was set at $237,500 for fiscal year 2025.
- Executive compensation programs utilize annual performance-based cash bonuses and equity awards to align long-term performance.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.